Advertisement
Albuquerque

Agilvax and Robotic Skies top Albuquerque's recent funding news

Albuquerque-based biotechnology company Agilvax has secured $2 million in grant funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced May 30 and financed by National Cancer Institute SBIR Development Center.

According to its Crunchbase profile, "Agilvax discover and develop new vaccines (including those in its current pipeline) for infectious and chronic diseases with unmet clinical need. The company identify and select lead vaccine candidates through its propietary affinity, optimizes those by in vitro and in vivo testing and develops them through pre-clinical and/or clinical testing until proof of concept is achieved establishing attractive out-licensing opportunities to Pharma or Biotech partners. Collaborations and partnerships are actively pursued within industry, academia and the government sector through NIAID."

The eight-year-old company has raised five previous funding rounds, including a $2.3 million grant in 2018.

The round brings total funding raised by Albuquerque companies in health care over the past month to $2.1 million. The local health care industry has seen three funding rounds over the past year, securing a total of $4.4 million in venture funding.

In other local funding news, robotics company Robotic Skies announced a Series A funding round on June 4, led by Boeing HorizonX Ventures.

According to Crunchbase, "Robotic Skies is a brokered global network of more than 150 independently-owned and operated repair stations that have the aviation expertise to provide maintenance and repairs on commercial unmanned systems. Robotic Skies draws on only the best FAA- and aviation authority-approved maintenance organizations currently maintaining manned aircraft to offer comprehensive field service programs designed to keep UAS flying safely, efficiently and affordably."

The company also raised a seed round in 2017.


This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.